Open AccessA retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
Author(s) -
Prabhat Agrawal,
Anita Jain,
Ashish Gautam,
A. N. Nigam,
Nikhil Pursnani,
Maaz Farooqui
Publication year - 2021
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/picr.picr_192_18
Subject(s) - pioglitazone , medicine , bladder cancer , retrospective cohort study , diabetes mellitus , urology , malignancy , glycemic , cancer , type 2 diabetes , oncology , endocrinology , insulin
Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The present retrospective study is aimed to assess the association of pioglitazone with urinary bladder cancer.